Literature DB >> 11373056

Alteration of the Langerhans islets in pancreatic cancer patients.

B M Schmied1, A B Ulrich, H Matsuzaki, C Li, H Friess, M W Böchler, A Andron-Sandberg, T E Adrian, P M Pour.   

Abstract

An abnormal glucose metabolism occurs in up to 80% of pancreatic cancer patients shortly or a few months before the first clinical admission. Reasons for this abnormality are obscure. We investigated immunohistochemically the pattern of islets in 14 pancreatic cancer specimens and used 14 chronic pancreatitis samples and 10 normal pancreata as controls. To study the topographical relationship of these islets to the cancer, islets in four different arbitrary zones within and around the cancer were evaluated. Ten out of 14 cancer specimens showed a significant loss of beta cells (p < 0.005) and eight of them also showed a significant increase of alpha cells (p < 0.005), all of them from hyperglycemic patients. Most affected islets were found within zone 1 (intratumoral) and zone 2 (peritumoral), to a lesser extent in zone 3 (acini close to tumor) and none in zone 4 (acini remote from tumor). No comparable changes were found in chronic pancreatitis patients. The incidence of 72% with alteration of islets in our material correlates with the frequency of abnormal glucose levels in human pancreatic cancer patients. Our findings support the notion that islet cell abnormalities is likely caused by substances released from cancer cells.

Entities:  

Mesh:

Year:  2000        PMID: 11373056     DOI: 10.1385/IJGC:28:3:187

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  45 in total

1.  The intravenous tolbutamide test as a diagnostic aid in carcinoma of the pancreas.

Authors:  D BERKOWITZ; L GREENBERG; S GLASSMAN
Journal:  Am J Med Sci       Date:  1962-02       Impact factor: 2.378

2.  The diagnosis of cancer of the pancreas.

Authors:  F J INGELFINGER
Journal:  N Engl J Med       Date:  1946-10-31       Impact factor: 91.245

Review 3.  Cancer and diabetes mellitus. A review of the literature.

Authors:  I I Kessler
Journal:  J Chronic Dis       Date:  1971-01

4.  The pancreatitis classification of Marseilles-Rome 1988.

Authors:  H Sarles; G Adler; R Dani; C Frey; L Gullo; H Harada; E Martin; M Norohna; L A Scuro
Journal:  Scand J Gastroenterol       Date:  1989-08       Impact factor: 2.423

5.  Glucagon and the A cell: physiology and pathophysiology (second of two parts).

Authors:  R H Unger; L Orci
Journal:  N Engl J Med       Date:  1981-06-25       Impact factor: 91.245

6.  Glucagon and the A cell: physiology and pathophysiology (first two parts).

Authors:  R H Unger; L Orci
Journal:  N Engl J Med       Date:  1981-06-18       Impact factor: 91.245

7.  Clinical and hormonal aspects of pancreatic diabetes.

Authors:  S Bank; I N Marks; A I Vinik
Journal:  Am J Gastroenterol       Date:  1975-07       Impact factor: 10.864

Review 8.  The problem of classification and staging of chronic pancreatitis. Proposals based on current knowledge of its natural history.

Authors:  S T Chari; M V Singer
Journal:  Scand J Gastroenterol       Date:  1994-10       Impact factor: 2.423

9.  [Chronic pancreatitis and diabetes].

Authors:  P Petrin; A Chiappetta; G Del Favero; R Farini; S Pedrazzoli
Journal:  Minerva Med       Date:  1983-01-14       Impact factor: 4.806

10.  C-peptide pattern in patients with pancreatic cancer.

Authors:  P Fogar; D Basso; M P Panozzo; G Del Favero; G Briani; C Fabris; F D'Angeli; T Meggiato; C Ferrara; M Plebani
Journal:  Anticancer Res       Date:  1993 Nov-Dec       Impact factor: 2.480

View more
  5 in total

Review 1.  Diabetes mellitus: a risk factor for pancreatic cancer?

Authors:  M Yalniz; P M Pour
Journal:  Langenbecks Arch Surg       Date:  2004-04-09       Impact factor: 3.445

2.  Beta cell transdifferentiation does not contribute to preneoplastic/metaplastic ductal lesions of the pancreas by genetic lineage tracing in vivo.

Authors:  Oliver Strobel; Yuval Dor; Amy Stirman; Amanda Trainor; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-07       Impact factor: 11.205

3.  Russian Consensus on Exo- and Endocrine Pancreatic Insufficiency After Surgical Treatment.

Authors:  Igor E Khatkov; Igor V Maev; Sayyar R Abdulkhalov; Sergey A Alekseenko; Ruslan B Allikhanov; Igor G Bakulin; Natalia V Bakulina; Andrey U Baranovskiy; Ekaterina V Beloborodova; Elena A Belousova; Sergey E Voskanyan; Lyudmila V Vinokurova; Vladimir B Grinevich; Vladimir V Darvin; Elena A Dubtsova; Tatiana G Dyuzheva; Vyacheslav I Egorov; Mikhail G Efanov; Roman E Izrailov; Vyacheslav L Korobka; Bogdan N Kotiv; Nikolay Yu Kokhanenko; Yury A Kucheryavy; Maria A Livzan; Vladimir K Lyadov; Karine A Nikolskaya; Marina F Osipenko; Victor D Pasechnikov; Ekaterina Yu Plotnikova; Oleg A Sablin; Vladimir I Simanenkov; Victor V Tsvirkun; Vladislav V Tsukanov; Alexey V Shabunin; Dmitry S Bordin; Professional Medical Society Pancreatic Club Russia
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

4.  Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis.

Authors:  Mina Waraya; Keishi Yamashita; Hiroshi Katoh; Akira Ooki; Hiroshi Kawamata; Hiroshi Nishimiya; Kazunori Nakamura; Akira Ema; Masahiko Watanabe
Journal:  BMC Cancer       Date:  2012-09-07       Impact factor: 4.430

Review 5.  What is the origin of pancreatic adenocarcinoma?

Authors:  Parviz M Pour; Krishan K Pandey; Surinder K Batra
Journal:  Mol Cancer       Date:  2003-01-22       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.